Showing results (1-10 of 33) with videos related to
Sort By:
Pageof 4
Clinical Case Reports|October 21, 2016
Acute cardiac decompensation in a patient with beta-thalassemia and diabetes mellitus following cessation of chelation therapyEirini Lioudaki, Martin WhyteReviews in Cardiovascular Medicine|March 1, 2022
Interrelation between heart failure with preserved ejection fraction and renal impairmentJennifer Ruth Joslin, Eirini Lioudaki, Emmanuel AndroulakisCurrent Pharmaceutical Design|November 15, 2011
Lipid lowering drugs and gallstones: a therapeutic option?Eirini Lioudaki, Emmanuel S Ganotakis, Dimitri P MikhailidisCurrent Pharmaceutical Design|November 15, 2011
Liver enzymes: potential cardiovascular risk markers?Eirini Lioudaki, Emmanuel S Ganotakis, Dimitri P MikhailidisCurrent Vascular Pharmacology|November 4, 2010
Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 yearsEirini Lioudaki, Emmanuel S Ganotakis, Dimitri P MikhailidisReviews in Cardiovascular Medicine|March 29, 2022
The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneysEirini Lioudaki, Jennifer Ruth Joslin, Eirini Trachanatzi, et al.Diagnostics (Basel, Switzerland)|October 27, 2022
Cardiac Imaging and Management of Cardiac Disease in Asymptomatic Renal Transplant Candidates: A Current UpdateEirini Lioudaki, Ariadni Androvitsanea, Ioannis Petrakis, et al.Current Pharmaceutical Design|January 3, 2013
Microalbuminuria: a neglected cardiovascular risk factor in non-diabetic individuals?Eirini Lioudaki, Matilda Florentin, Emmanuel S Ganotakis, et al.Current Pharmaceutical Design|December 7, 2010
The estrogenic burden on vascular risk in male-to-female transsexualsEirini Lioudaki, Emmanuel S Ganotakis, Dimitri P Mikhailidis, et al.Hormones (Athens, Greece)|January 25, 2014
Subclinical hypothyroidism and vascular risk: an updateEirini Lioudaki, Niki G Mavroeidi, Dimitri P Mikhailidis, et al.Pageof 4